Adherent patients on tirzepatide in an Australian digital weight-loss program lost an average of 22.7% body weight at 12 months, but only 16.1% of enrollees stayed in the program that long.
22.7% weight loss at 12 monthsAmong the 16.1% of enrollees who adhered to the tirzepatide-supported digital program for a full year, with 100% achieving at least 5% body weight reduction
What the researchers found
At 6 months, 31.7% of the 4,309 enrollees met adherence criteria, with mean weight loss of 16.9% (±8.6; 98.0% achieved ≥5% reduction). At 12 months, 16.1% were adherent with mean weight loss of 22.7% (±7.2; 100% achieved ≥5% reduction). First-month weight loss was the strongest predictor of 6- and 12-month outcomes. Sustained weekly weight tracking and health coach messaging were strongly associated with retention and greater weight loss. Paradoxically, very frequent weight tracking in month one correlated with poorer outcomes. Side effects were common but mostly mild/moderate and did not predict dropout.
Why it matters
Clinical trials show tirzepatide can produce dramatic weight loss, but real-world results often differ. This is one of the largest real-world studies of tirzepatide in a digital health setting, revealing that while the drug delivers exceptional results for engaged users, the majority of people drop out within months. This adherence gap is the central challenge for translating peptide-based obesity treatments into population-level health improvements.
How the study worked
Retrospective observational study of all patients initiating tirzepatide through the Juniper AU digital weight-loss service between September 2024 and April 2025 (n=4,309). The cohort was predominantly female (92.9%), Caucasian (81.9%), mean age 41.5 years, mean BMI 32.9. Adherence required minimum medication orders plus weight entries at defined timepoints. Full cohort analysis used last observation carried forward imputation. Multivariable models identified predictors of outcomes.
What this study cannot tell us
This is a retrospective observational study without a control group or randomization. The cohort was predominantly young, female, and Caucasian, limiting generalizability. The adherence definition required specific medication orders and weight entries, which may not capture all engaged users. Last observation carried forward imputation likely overestimates weight loss for dropouts. The digital weight-loss service context may not represent typical clinical care. Selection bias exists as participants self-selected into a commercial program.
How to read the evidence
This is a large real-world observational study (n=4,309) without a control group. While the sample size is substantial, the retrospective design, self-selected population, and lack of randomization limit causal conclusions. However, it provides valuable real-world effectiveness data that complements clinical trial evidence.
When this study was published
Published in 2026 with data from September 2024 to April 2025, this is among the first large-scale real-world tirzepatide studies and directly reflects current clinical practice patterns.
The bigger picture
Tirzepatide (brand name Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist peptide that has shown the largest weight loss of any approved obesity drug. However, this study highlights the growing tension in obesity medicine: the drugs work remarkably well, but real-world adherence — driven by cost, access, side effects, and behavioral factors — severely limits their impact. The finding that digital coaching and engagement patterns predict success points toward integrated care models as the path forward, combining peptide therapeutics with sustained behavioral support.
Questions still open
- Why does very frequent weight tracking in the first month predict worse outcomes — is it a marker of anxiety or unrealistic expectations?
- What interventions could improve the 16% 12-month adherence rate to make population-level impact?
- How do these real-world results compare to tirzepatide outcomes in traditional clinical settings without digital support?
Common questions
What is tirzepatide and how is it different from semaglutide?
Why do so many people stop taking weight-loss peptide drugs?
Read the original research
Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.
Diabetes, obesity & metabolism
Citation
Talay, Louis; Hom, Jason; Scott, Tamara; Ahuja, Neera. (2026). Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70462